Antibody screening using a human iPSC-based blood-brain barrier model identifies antibodies that accumulate in the CNS.

ABSTRACT: Drug delivery across the blood-brain barrier (BBB) remains a significant obstacle for the development of neurological disease therapies. The low penetration of blood-borne therapeutics into the brain can oftentimes be attributed to the restrictive nature of the brain microvascular endothelial cells (BMECs) that comprise the BBB. One strategy beginning to be successfully leveraged is the use of endogenous receptor-mediated transcytosis (RMT) systems as a means to shuttle a targeted therapeutic into the brain. Limitations of known RMT targets and their cognate targeting reagents include brain specificity, brain uptake levels, and off-target effects, driving the search for new and potentially improved brain targeting reagent-RMT pairs. To this end, we deployed human-induced pluripotent stem c

SUBMITTER: Georgieva JV 

PROVIDER: S-EPMC7513543 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature